Slide 1: Q3 2023 results presentation
January 2023 – September 2023 – Q3 2023 results presentation
Slide 2: Forward-looking statement
Forward-looking statement This presentation contains certain forward-looking statements and opinions. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the future that, for example, contain wording such as "beli
Slide 3: Agenda
Agenda Q3 in short Business updates Financial results Strategy and outlook Q&A Henrik Molin CEO & co-founder Charlotte Goodwin CFO Q1 Q2 Q3 Q4 3
Slide 4: Q3 in short
Q3 in short Q1 Q2 Q3 Q4 4
Slide 5: Quarterly progress
Celebrating another successful quarter of growth, with adjusted EBITDA increasing to EUR 1.1m for the quarter showcasing the Group’s continued dedication to financial excellence and sustainable success 26% 27% 26% Adjusted EBITDA YTD Q3 YTD 2023 Q3 YTD 2023 organic increased to revenue growth revenu
Slide 6: Business updates
Business updates 4b Physitrack
Slide 7: Our two business lines positioned for digital healthcare demand
Our two business lines have us well-positioned to capitalize on increasing digital healthcare demand and corporate wellbeing challenges Q@= Mental Wellbeing ‘Your Results mel sn wo ae then nd ae =I ! = ero = Lifecare Wellness Seamless and One platform, All ’ Efficient care areas of employee " Soluti
Slide 8: Lifecare quarterly developments
Lifecare quarterly developments Q3 Highlights: 8% growth in license numbers • Continued focus across the entire division to drive efficiencies leading to EBITDA expansion. within Lifecare • Physicourses was successfully integrated into the Lifecare service offering. Not only 57,000 does this enrich
Slide 9: Wellness quarterly developments
Wellness quarterly developments Q3 Highlights: Revenue, Wellness segment 4.5 4.0 • Growth for the current quarter represents pure organic growth, with this being the 64% 3.5 first quarter where no acquisitions took place in the prior year comparative. 3.0 2.5 • Significant enhancements to the existi
Slide 10: Accelerating Product and Content Development with AI
Accelerating Product and Content Development with AI - Multiple AI-powered parallel workstreams in Physitrack, Physicourses and Champion Health. - Enhancement of the Physitrack library with wide ethnic diversity in new and existing exercises, - Introduction of LLM-based Co-pilot in Physitrack to sim
Slide 11: Financial Results
Financial Results Q1 Q2 Q3 Q4 1 1
Slide 12: Q3 Financial Highlights
Q 1 2 Q3 Financial Highlights 3 month revenue 3 Month EBITDA 14% 16% €3.9m (Q3 2022: €3.4m) €0.8m (Q3 2022: €0.7m) Operating cashflow 12 month organic revenue 27% 18% growth €2.1m (Q3 2022: €1.7m) 3 month adjusted EBITDA 3 month adjusted EBITDA margin 15% -pp €1.1m (Q3 2022: €0.9m) 27% (Q3 2022: 27%
Slide 13: Maintaining revenue growth
Q 1 2 Maintaining revenue growth In-line with medium term growth targets Group Revenue Lifecare revenue growth 3.0 Wellness revenue growth 2.5 4.5 17% 4.0 2.5 12% 2.0 3.5 2.0 3.0 28% 1.5 2.5 1.5 2.0 1.0 1.5 1.0 1.0 0.5 0.5 0.5 - - - Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q
Slide 14: EBITDA: Continued strong growth
Q 1 2 EBITDA Continued strong growth 3.5 3.0 14% €0.7M 2.5 €1.3M €2.6M 2.0 €'million 82% €2.9M 1.5 €1.4M 1.0 ADJUSTED EBITDA €1.2m Margin ADJUSTED EBITDA 0.5 Margin 29% 26% - 9 MONTHS 2022 EBITDA Adjusting it ems* 9 MONTHS 2022 Adjusted 9 MONTHS 2023 EBITDA Adjusting it ems* 9 MONTHS 2023 Adjusted E
Slide 15: Adjusted EBITDA by division
Q 1 2 Adjusted EBITDA 4.0 3.5 EBITDA by division 3.0 0.9 14% 2.5 3.4 1.1 Q3 2023 0.3 6% 47% 2.0 0.9 (0.7) 1.5 1.0 0.9 3.2 1.0 Q3 2022 0.1 3% 49% (0.7) 0.5 0.9 0.7 - (1.0) (0.5) - 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 2022 ADJ EBITDA 2023 ADJ EBITDA Lifecare Wel lness Group Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 16: Cashflow
Q 1 2 Cashflow 4.0 3.0 (0.8) Available liquidity (0.2) €2.3m 2.0 2.9 €1.9m undrawn on facility (2.5) 1.9 1.0 - 0.6 0.4 2.9 - 1 Jan 2023 Opening Adjusted EBITDA Working capital Interest expense Purchase of Deferred Adjusting it ems Drawdown of Fx 30 September 2023 Net cash intangibles consideration b
Slide 17: Continued focus on free cash-flow
Q 1 2 Continued focus on free cash-flow - Q122 Q222 Q322 Q422 Q123 Q223 Q323 (0.2) Expected cash-flow (0.4) positive Q423 (0.6) (0.8) (1.0) (1.2) (1) Free cash flow is defined as net cash from operating activities, less purchase of intangible assets and property, plant and equipment and finance cost
Slide 18: Balance sheet
Q 1 2 Balance sheet Strong liquidity position despite deferred consideration payments in Q1 30 September 2023 30 September 2022 Euros '000 Goodwill, intangibles and PPE 35,814 37,889 Cash and cash equivalents 440 1,075 Borrowings (3,787) (823) Trade and other receivables 4,428 3,384 Trade and other
Slide 19: Strategy and outlook
Strategy and outlook Q1 Q2 Q3 Q4 19
Slide 20: Our unique value proposition
Our unique value proposition Holistic offering, powered by top-of-the-line tech True product market fit Prices in relation to the market rather than growth expectations Catering to consumer trends Improved patient outcomes, through more personalized, data-driven care Positioned to capitalize on grow
Slide 21: How it all comes together - investing in Physitrack
How it all comes together - investing in Physitrack Market outlook and position Focus Areas High-reaching financial goals Top-line growth Growing market supported 1. Market growth dynamics by underlying macro Physitrack aims to achieve annual organic trends sales growth exceeding 30% in the medium t
Slide 22: Q&A
Q&A Q1 Q2 Q3 Q4 22